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Mammographic screening: A common
cause of statistics!A recent paper in IJS by Retsky et al.1 concern-
ing the hazards of mammographic screening in
pre-menopausal women provoked a blizzard of
correspondence in our letter pages.2 This was but
an adumbration of the storm that was to follow
in the print pages, rapid responses online and pub-
lished letters in the British Medical Journal over
the last two or three weeks. At the outset I have
to state a conflict of interest in writing this edito-
rial: I have for a long time nailed my colours to the
mast as a sceptic about the claims of mammog-
rahic screening.3,4
The story starts with a paper by Jørgensen
and Gøtzsche5 describing the contents of invita-
tions to women for publicly funded mammogra-
phy. They argue that the benefits and harms of
screening are delicately balanced and women
should therefore be given sufficient information
to decide for themselves on an informed basis.
None of the invitations they analysed from
Australia, New Zealand, Canada, Denmark, Nor-
way, Sweden and the UK contained adequate in-
formation on the harms of screening and all
described the benefits in relative rather than
absolute terms, an un-interpretable construct
for most lay women and for that matter most
doctors. They concluded that publicly funded
screening programmes also have a conflict of in-
terest, as a high acceptance rate is a prerequisite
of cost effectiveness, yet informed consent is
a prerequisite for a woman to make a judgement
about harm versus benefit. These concerns were
dismissed in an accompanying editorial by
Michael Dixon6 who concluded that:
‘‘Criticisms about the early trials are no longer
relevant. Breast screening has moved on and is
looking to the future, and so should the sceptics’’.1743-9191/$ - see front matter ª 2006 The Surgical Associates Ltd
doi:10.1016/j.ijsu.2006.04.001Little did he realise that those words would
return to haunt him in the very next issue of the
BMJ.
For a start there are no ‘‘new trials’’ of screen-
ing, the old ones with all their flaws are all that
we’ve got.7 Next breast screening has only ‘‘moved
on’’ by looking to the past as neatly pointed out by
Hazel Thornton8, a consumer advocate, in her rapid
response that was published on 25th March:
‘‘If breast screening is to move on, then it’s time
the proponents of breast screening moved on..
Women today do not want to be patronised, or
fobbed off with unbalanced and insufficient in-
formation, but to be treated with respect, so that
they can make up their own minds.’’
Yet worse was to follow. In the same issue of the
BMJ (25th March), Sophia Zackrisson et al. pub-
lished a paper entitled ‘‘Rate of over-diagnosis of
breast cancer 15 years after the end of Malmo¨
mammographic screening trial: follow up study’’.9
Over-diagnosis of breast cancer doesn’t mean false
positive rates but the detection and treatment of
cancers that left undetected would never threaten
a woman’s life and of which she would live, in
blissful unawareness until she died naturally of
old age. We had always assumed that there was
an over-diagnosis of duct carcinoma in situ
(DCIS), some of which had the potential of pro-
gressing to an invasive and life-threatening pheno-
type.10 However, there was clear evidence that
about 10% of invasive cancers detected and
treated radically as a result of screening, would
never threaten life. In the accompanying commen-
tary Møller and Davies11 agreed and calculated
that at best, for every woman whose death from
breast cancer is prevented, two over-diagnosed
patients pay the price by becoming breast cancer. Published by Elsevier Ltd. All rights reserved.
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is a conservative estimate as pointed out in the
rapid response from Welch et al.12 who recalcu-
lates the same data and shows that they are com-
patible with a 25% over-diagnosis rate. This is the
same Gilbert Welch who coined the term
‘‘pseudo-cancer’’ and published the best book
I’ve ever read on the subject.13
Whether it’s 10% or 25% surely this is additional
information about the adverse effects of screen-
ing that women are justified to know about
before accepting an invitation to screening or
perhaps you believe we shouldn’t bother their
pretty little heads with all this tricky and scary
information. You can imagine how surgeons would
be treated today by adopting such a discredited
type of paternalism. Well the lay press have been
quick on the uptake and a highly regarded glossy
popular science magazine in France has already
published a five-page critique on the subject
(Fig. 1).14
Figure 1 Women need sufficient information about
the risks as well as benefits of breast cancer screening
in order to make an informed choice (top right: the
famous Kansas City Country Club Plaza where Pink/Red
water is used to commemorate breast cancer awareness
week). Copyright www.istockphoto.comYet there is more to come. In the same period
under discussion a paper was published online by
the European Journal of Cancer that is potentially
explosive.15 Per-Henrik Zahl a Norwegian epidemi-
ologist and others re-visited the official Swedish
data-base that matches individuals by name and
number to time, place, cancer diagnosis and can-
cer death. They matched up the exact numbers
of women in Kopparberg and O¨stergo¨tland, the
famous two counties of the trial upon which most
National screening programmes were predicated.
During the period recorded in the study they found
that there were nearly 400 breast cancers and
nearly 100 breast cancer deaths that were missing
in the reports of the trial.16 Aminormal-distribution
of these missing cases could negate the findings
of the trial. I reserve judgement on this paper
as the methodology although apparently simple
might be subject to informed criticism. If sup-
ported then we have to accept that the whole
screening evidence is built on foundations of
sand, however, if the re-analysis is found to be
flawed then I wouldn’t want to be the one to
face the wrath of the screening establishment.
This might almost be as fierce as the fury of the
lay women, should they learn that they have
been hoodwinked all along. In the meantime, I
shall watch the fall out from this farrago from
the safety of my bunker at a secret location in
North West London.
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